Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 39

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 39
---
 Mandatory Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the Company. A further US$2,000,000 of the Third Mandatory Additional Note was issued subsequent to the 2024year end and remains outstanding. Moreover, the Company has access to an equity line of credit facility of up to US$100,000,000 from White Lion Capital, of which approximately US$11.66 million has been drawn and become equity to date.

The Company can make no assurance
that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If
one or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall,
there would likely be a material adverse effect on the Company and its financial statements.

The consolidated financial
statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. If the going concern basis
was not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets
and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.

The fertility market in which NewGenIvf participates is competitive, and if NewGenIvf does not continue to compete effectively, its results of operations could be materially and adversely affected.

The market for NewGenIvf’s
solutions is competitive and is likely to attract increased competition, which could make it hard for it to succeed. NewGenIvf faces
significant competition from other fertility companies and other players in the fertility market. Some of NewGenIvf’s competitors
are more established, have a longer operating history and a larger client base, benefit from greater brand recognition and have substantially
greater financial, technical and marketing resources than NewGenIvf does. NewGenIvf’s competitors may compete with NewGenIvf in
a variety of ways, including seeking to develop or integrating solutions and services that may become more efficient or appealing to
NewGenIvf’s existing and potential clients, achieving superior clinical outcomes, having access to a network of more high-quality
fertility specialists, establishing more comprehensive data reporting and sharing systems, conducting brand promotions and other marketing
activities, and making investments in and acquisitions of NewGenIvf’s business partners. While NewGenIvf believes that one of its
key competitive advantages is its ability to provide a broad range of services, and NewGenIvf does not believe any competitors have developed